CO2018005361A2 - Formulaciones inyectables de toxina botulínica y sus métodos de uso que poseen efecto terapéutico o cosmético de larga duración - Google Patents

Formulaciones inyectables de toxina botulínica y sus métodos de uso que poseen efecto terapéutico o cosmético de larga duración

Info

Publication number
CO2018005361A2
CO2018005361A2 CONC2018/0005361A CO2018005361A CO2018005361A2 CO 2018005361 A2 CO2018005361 A2 CO 2018005361A2 CO 2018005361 A CO2018005361 A CO 2018005361A CO 2018005361 A2 CO2018005361 A2 CO 2018005361A2
Authority
CO
Colombia
Prior art keywords
botulinum toxin
methods
long
toxin formulations
cosmetic effects
Prior art date
Application number
CONC2018/0005361A
Other languages
English (en)
Inventor
Curtis L Ruegg
Jacob M Waugh
Original Assignee
Revance Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58630886&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2018005361(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Revance Therapeutics Inc filed Critical Revance Therapeutics Inc
Publication of CO2018005361A2 publication Critical patent/CO2018005361A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/0059—Cosmetic or alloplastic implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Abstract

RESUMEN La presente invención proporciona composiciones inyectables novedosas que comprenden toxina botulínica y que pueden administrarse a un sujeto para varios fines terapéuticos, estéticos y/o cosméticos. Las composiciones inyectables abarcadas por la invención muestran una o más ventajas sobre las formulaciones de toxina botulínica convencionales, incluyendo la antigenicidad reducida, una tendencia reducida para someterse a la dispersión localizada indeseada después de la inyección, duración aumentada de la eficiencia clínica o la potencia relativa aumentada, el inicio más rápido de la eficiencia clínica y/o la estabilidad mejorada. De acuerdo con la invención, un solo tratamiento de las composiciones por inyección proporciona respuestas clínicas significantes y al menos una duración del efecto de 6 meses en un sujeto sometido a tratamiento, como se proporciona por los métodos de tratamiento descritos.
CONC2018/0005361A 2015-10-29 2018-05-23 Formulaciones inyectables de toxina botulínica y sus métodos de uso que poseen efecto terapéutico o cosmético de larga duración CO2018005361A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562248255P 2015-10-29 2015-10-29
PCT/US2016/059492 WO2017075468A1 (en) 2015-10-29 2016-10-28 Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect

Publications (1)

Publication Number Publication Date
CO2018005361A2 true CO2018005361A2 (es) 2018-10-10

Family

ID=58630886

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0005361A CO2018005361A2 (es) 2015-10-29 2018-05-23 Formulaciones inyectables de toxina botulínica y sus métodos de uso que poseen efecto terapéutico o cosmético de larga duración

Country Status (16)

Country Link
US (2) US20180311333A1 (es)
EP (1) EP3368071B1 (es)
JP (2) JP6955491B2 (es)
KR (1) KR20180077202A (es)
CN (1) CN109069608A (es)
AU (2) AU2016343748A1 (es)
BR (1) BR112018008684A2 (es)
CA (1) CA3003447A1 (es)
CO (1) CO2018005361A2 (es)
DK (1) DK3368071T3 (es)
ES (1) ES2907652T3 (es)
IL (2) IL259016A (es)
MX (1) MX2018005256A (es)
RU (1) RU2018119765A (es)
SG (2) SG10202004337WA (es)
WO (1) WO2017075468A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101453963B1 (ko) * 2005-03-03 2014-10-22 레반스 테라퓨틱스, 아이엔씨. 보툴리눔 독소의 국소 적용 및 경피 전달을 위한 조성물 및 방법
MX344583B (es) * 2009-06-25 2016-12-20 Revance Therapeutics Inc Formulaciones de toxina botulinica libres de albumina.
JP5951490B2 (ja) * 2009-10-21 2016-07-13 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 非複合ボツリヌス神経毒素を精製するための方法およびシステム
JP6955491B2 (ja) 2015-10-29 2021-10-27 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 治療効果又は美容効果の長い持続時間を有する、注射用ボツリヌス毒素製剤及びこれらの使用方法
BR112019010131A2 (pt) 2016-11-21 2019-10-08 Eirion Therapeutics Inc entrega transdérmica de agentes grandes
MX2019011196A (es) * 2017-03-22 2020-01-20 Bonti Inc Neurotoxinas botulinas para uso en terapia.
JP2020520917A (ja) * 2017-05-18 2020-07-16 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 頸部ジストニアの治療方法
EP3703738A4 (en) * 2017-11-03 2021-09-08 ReVance Therapeutics, Inc. BOTULINIC TOXIN FORMULATIONS AND METHODS OF USE THEREOF IN PLANTARY FASCIITIS, WITH EXTENDED DURATION OF EFFECT
CA3084175A1 (en) * 2017-12-04 2019-06-13 Revance Therapeutics, Inc. Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration
CN112955166A (zh) * 2018-09-13 2021-06-11 阿勒根公司 治疗咬肌肥大的方法
KR20220008311A (ko) * 2019-05-14 2022-01-20 에이리온 테라퓨틱스, 인코포레이티드 최대 효과 지연 및/또는 반응 지속시간 연장
EP4121169A4 (en) * 2020-03-18 2024-04-24 Revance Therapeutics Inc INJECTABLE BOTULINUM TOXIN METHODS FOR TREATING HEADACHES
KR102397708B1 (ko) * 2020-04-29 2022-05-16 한국화학연구원 탄닌산을 포함하는 보툴리눔 독소 약제학적 조성물
KR102324855B1 (ko) * 2020-05-20 2021-11-11 오스템임플란트 주식회사 보툴리눔 독소를 포함하는 약제학적 액상 조성물
KR102266384B1 (ko) * 2021-01-25 2021-06-21 주식회사 울트라브이 필러용 생분해성 고분자 미세입자, 이를 포함한 필러용 동결건조체, 그 제조방법 및 상기 동결건조체를 포함하는 필러용 주사제
CN117561075A (zh) * 2021-04-26 2024-02-13 上海科技大学 肉毒杆菌神经毒素的肌内注射组合物
KR20230171400A (ko) * 2022-06-10 2023-12-20 (주)메디톡스 보툴리눔 독소 안정화 조성물, 이를 포함하는 보툴리눔 독소 제제 및 이에 사용하기 위한 폴리펩티드

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877278A (en) 1992-09-24 1999-03-02 Chiron Corporation Synthesis of N-substituted oligomers
US6444209B1 (en) 1996-10-28 2002-09-03 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
WO2001058472A2 (en) 2000-02-08 2001-08-16 Allergan, Inc. Botulinum toxin pharmaceutical compositions
DE10043982A1 (de) * 2000-09-05 2002-03-14 Armin Maurer Verfahren zur Verbesserung des Haarwuchses menschlichen Kopfhaares
US20100168023A1 (en) 2008-12-31 2010-07-01 Revance Therapeutics, Inc. Injectable Botulinum Toxin Formulations
MX344583B (es) * 2009-06-25 2016-12-20 Revance Therapeutics Inc Formulaciones de toxina botulinica libres de albumina.
PT2661276T (pt) * 2011-01-07 2017-10-06 Revance Therapeutics Inc Composição tópica que inclui uma tóxina botulínica e um corante
CA2867511A1 (en) * 2012-03-22 2013-09-26 Revance Therapeutics, Inc. Method of treatment of wrinkles using topical chemodenervating agents
WO2014066916A2 (en) * 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
JP6955491B2 (ja) 2015-10-29 2021-10-27 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 治療効果又は美容効果の長い持続時間を有する、注射用ボツリヌス毒素製剤及びこれらの使用方法

Also Published As

Publication number Publication date
BR112018008684A2 (pt) 2018-11-27
CA3003447A1 (en) 2017-05-04
AU2023241373A1 (en) 2023-10-26
IL286472A (en) 2021-10-31
MX2018005256A (es) 2019-09-04
JP2018531984A (ja) 2018-11-01
EP3368071A4 (en) 2019-05-29
RU2018119765A3 (es) 2020-03-17
CN109069608A (zh) 2018-12-21
DK3368071T3 (da) 2022-05-02
AU2016343748A1 (en) 2018-05-17
KR20180077202A (ko) 2018-07-06
JP2022008814A (ja) 2022-01-14
JP6955491B2 (ja) 2021-10-27
US20180311333A1 (en) 2018-11-01
ES2907652T3 (es) 2022-04-25
WO2017075468A1 (en) 2017-05-04
IL259016A (en) 2018-06-28
SG10202004337WA (en) 2020-06-29
SG11201803566TA (en) 2018-05-30
US20220062400A1 (en) 2022-03-03
RU2018119765A (ru) 2019-12-02
EP3368071B1 (en) 2022-01-26
EP3368071A1 (en) 2018-09-05

Similar Documents

Publication Publication Date Title
CO2018005361A2 (es) Formulaciones inyectables de toxina botulínica y sus métodos de uso que poseen efecto terapéutico o cosmético de larga duración
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
ECSP19010079A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CL2019002255A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas.
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
BR112017018368A2 (pt) composições contendo rna para o tratamento de doenças tumorais
UY36665A (es) Derivados de ciclohexano sustituidos con amidas
CO2020008231A2 (es) Formulaciones inyectables de toxina botulínica y métodos de uso de las mismas que tienen una alta tasa de respuesta y una larga duración del efecto
BR112015018270A2 (pt) composições que compreendem 15-ohepa e métodos de uso das mesmas
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
AR101236A1 (es) Composiciones para el cuidado oral
UY35651A (es) Pirazolpiridinas sustituidas
BR112016029024A8 (pt) composto, composição farmacêutica e uso
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
CO2018013828A2 (es) Composiciones farmacéuticas de oligómero de morfolino fósforodiamidato
GT201700126A (es) Ácidos piridil-cicloalquil-carboxílicos sustituidos composiciones que los contienen y usos de los mismos
ECSP20020949A (es) Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos
CL2020002519A1 (es) Composiciones de erenumab y usos de las mismas
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
CL2018002848A1 (es) Formulaciones liquidas de fosfoplatino
NI201500172A (es) Composiciones farmacéuticas
UY36983A (es) Pirazolopiridinaminas sustituidas
AR099681A1 (es) Composiciones de grapiprant y métodos para su utilización